TheEdgeResearch
Home / Stocks / VRTX

Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ Healthcare Biotechnology
$466.82 ▲ +0.01%
Market Cap
$118.48B
Sector
Healthcare
Industry
Biotechnology
Beta
0.31
52-Wk Range
362.5-507.92
CEO
Reshma Kewalramani
Country
US
Currency
USD

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a r…

Open full interactive analysis & DCF →